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846P Patterns of therapy in pelvic lymph node positive prostate cancer in
Europe and Asia: A real-world data analysis
M. Prentice1, S. Mpima2, P. Nasuti2, A. Martinez-Pinillos2, I. Wong3, K. Durno1, R. Davda1,
H. Payne1
1Oncology, University College London Hospital UCLH NHS Foundation Trust, London,
UK, 2Real World and Analytics Solutions, IQVIA, London, UK, 3Department of Policy and
Practice, UCL School of Pharmacy, London, UK
Background: Treatment for node positive prostate cancer can vary from palliation to radi-
cal therapy. Guidance for N1 prostate cancer is unclear but evidence supports a multimodal
approach including radical radiotherapy, hormonal manipulation and possible surgery
while a survival benefit for neoadjuvant docetaxel has been demonstrated. Recent improve-
ments in diagnostic techniques and technical advances in radiation therapy including inten-
sity modulated radiotherapy (IMRT) which is capable of delivering a radical dose of
radiation to pelvic nodes within acceptable toxicity profiles are anticipated to result in an
increased use of radiation in this patient population. This study assesses changes in treat-
ment modality for N1 prostate cancer over time to reflect real world practice.
Methods: Patient data from 17,695 prostate cancer cases taken from a cross-sectional
survey of physicians in France, Germany, Italy, Spain, UK, China, Japan and S. Korea
between Jan 1997 – Dec 2016 was reviewed. Patients with non-metastatic, node positive
cancer were included for analysis. Any exposure to any of three therapy types (systemic,
radiation, surgery) prior to recurrence.
Results: 2542 patients were included in the analysis. Over the time studied, the use of
surgery has decreased (from 36% in pre 2009 to 16% in 2016) and initially, this decline
was matched by a rise in the use of systemic therapy alone (37% to 51%). Since 2011
systemic therapy alone has reduced to 40%. In the same time period, there has been an
increase in the use of radiation (with or without systemic therapy) to treat node positive
prostate cancer (15% to 29%). The average increase in radiotherapy use across
European countries was 11% (range Italy 2% - Spain 19%). A group of patients receiv-
ing combined surgery, radiation and systemic therapy comprise 11% of all cases, a fig-
ure that does not vary over time.
Conclusions: These data have demonstrated an international change in the manage-
ment of node positive prostate cancer with decreasing use of surgery and increasing use
of radiation. Although initially rising, the recent decline in the use of lone systemic ther-
apy is likely to represent an increasing view that N1 prostate cancer is no longer a defin-
itively palliative diagnosis.
Legal entity responsible for the study: IQVIA.
Funding: IQVIA.
Disclosure: I. Wong: Honoraria: Janssen, Sanofi Aventis. H. Payne: Honoraria,
advisory boards, travel expenses, consultant: AstraZeneca, Astellas, Janssen, Sanofi
Aventis, Takeda, Amgen, Ipsen, Ferring, Sandoz and Novartis; Work support: UCLH/
UCL Comprehensive Biomedical Research Centre. All other authors have declared no
conflicts of interest.
847P The prognostic significance of the 2014 International Society of
Urological Pathology (ISUP) grading system in patients with high-risk
prostate cancer
J. Liu, J. Zhao
Department of Urology, Institute of Urology, West China Hospital, SiChuan Univer, West
China Hospital, Sichuan University, Chengdu, China
Background: Since the new 2014 grading system was recommended by international
society of urological pathology (ISUP), it has been validated in patients with localized
prostate cancer(PCa) with excellent prognostic value. However, its predictive power in
high-risk PCa has not been verified.
Methods: A total of 420 patients with high-risk PCa underwent radical
prostatectomy(RP) were included. The predictive accuracy of the 2005 and 2014 grad-
ing systems were validated and compared. Biochemical-recurrence free survival (BRFS)
was set as the endpoint.
Results: Compared to the 2005 system, the 2014 system could fairly well distinguish
BRFS of patients into five groups with higher predictive accuracy(C-index: 0.599 vs
0.646). In multivariate analyses, together with baseline prostate specific antigen, extrap-
rostatic extension and perineural invasion status, the new system was independent pre-
dictor for BRFS in these population. The relatively higher proportion of tertiary
Gleason pattern 5 (TGP5) among patients with Gleason grade group 3(GGG3) could
be considered as an important interfering factor leading to the overlap of survival
between GGG4 and GGG3.
Conclusions: This is the first study to validate the new 2014 ISUP grading system in
patients with high-risk PCa underwent RP. The new system could better separate
patients into five groups with higher predictive accuracy over the old one. It should be
paid attention that, the existence of TGP5 need to be routinely reported in clinical
practice, which could help retaining the predictive ability of the new grading system.
Due to miscellaneous factors among these patients, the prognostic prediction need to
be comprehensively evaluated.
Legal entity responsible for the study: Department of Urology, Institute of Urology,
West China Hospital, SiChuan University.
Funding: National Natural Science Foundation of China (NSFC 81402110, 81672547,
81572380, and 81272820); Science and Technology Support Program of Sichuan
Province (2015SZ0142); 1.3.5 project for disciplines of excellence, West China
Hospital, Sichuan University.
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848P Overall survival (OS) implications for patients with mCRPC through
coverage and adoption of nuclear AR-V7 testing by healthcare systems
J. Hornberger1, R.P. Graf2, M. Hulling3, G. Attard4, A. Allan5, R. Dittamore2, H.I. Scher3
1Clinical Economics and Outcomes Research, Genomic Health, Redwood City, CA, USA,
2Translational Research, Epic Sciences, Inc., San Diego, CA, USA, 3Genitourinary
Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA,
4Medical Oncology, The Institute of Cancer Research and The Royal Marsden, London,
UK, 5Oncology and Anatomy and Cell Biology, Western University, London, ON, Canada
Background: Nuclear-localized AR-V7 testing of circulating tumor cells (CTCs) has
been validated as a predictive biomarker of chemotherapy response and ARSI non-
response in 2ndþ line therapy for metastatic castration-resistant prostate cancer
(mCRPC). A validation study showed that AR-V7(þ) pts have improved OS with tax-
ane chemotherapy, and AR-V7(-) pts have improved OS with ARSi. We assessed the
effect of AR-V7 testing on OS when generalized to non-trial clinical settings, as found
in third-party US healthcare systems.
Methods: The causal effect of treatment and nuclear AR-V7 status on OS was estimated
from risk-adjusted hazard rates of the MSK, ICR, LHS validation study. Therapeutic
strategies assessed were (1) taxanes only, (2) ARSi only, (3) current US utilization rate
of ARSis, and (4) nuclear AR-V7-guided treatment. Quality of life adjustments were
extracted from meta-analysis of large cohort studies. We applied US utilization rate of
consecutive ARSi administration (abiraterone after enzalutamide, or enzalutamide
after abiraterone) and compared to switching with taxane-based chemotherapy (doce-
taxel after abiraterone, or docetaxel after enzalutamide).
Results: The following table shows OS, adjusted and unadjusted for quality of life, and
treatment by strategy. The net effects on OS were robust to variation on the clinical
effects, and on systems covariates, e.g., demographic, patient, and payer case-mix.
Table: 848P
2nd line mCRPC therapy
strategy
% ARSi OS (months)
QALY (Unadj / Adj.)
Net OS gain
(months) QALY
(Unadj / Adj)
Only use taxanes 0% 19.2 / 12.2 -3.7 /-2.0
Only use ARSi’s 100% 25.4 / 15.6 2.5 / 1.4
Current use of ARSi (US) 60% 22.9 / 14.2 - REF -
AR-V7 guided treatment 77% 27.3 / 16.7 4.4 / 2.5
Conclusions: Health outcome modeling of the validation data support that current use
and access to 2nd ARSi therapy can improve OS of patients over strict use of taxane che-
motherapy (þ3.7mo OS). 2ndþ line nuclear-localized AR-V7 guided treatment for
men with progressive mCRPC provides higher OS than non-guided, almost doubling
the gain (þ4.4 mo OS) observed with current US utilization rate of ARSi versus taxanes
only. Cost effectiveness analyses of the adoption/coverage of nuclear AR-V7 testing in
healthcare systems is ongoing.
Legal entity responsible for the study: MSKCC.
Funding: NIH/NCI P50-CA92629 SPORE in Prostate Cancer, NIH/NCI Cancer
Center Support Grant P30-CA008748, NIH grant R01-CA207220, Department of
Defense Prostate Cancer Research Program (PC121111 and PC131984), Prostate
Cancer Foundation Challenge Award, and David H. Koch Fund for Prostate Cancer
Research were used to support the design and conduct of the study at Memorial Sloan
Kettering Cancer Center. Funds from the London Regional Cancer Program Catalyst
Grant and TELUS Ride For Dad/Prostate Cancer Fight Foundation were used to sup-
port the study at London Health Sciences Centre. A Medical Council Clinical Research
Fellowship (AJ) and NHS funding to the Royal Marsden and Institute of Cancer
Research Biomedical Research Centre.
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Pharma, Janssen, Sanofi, Takeda, Ventana Medical Systems; Research funding: Arno
Therapeutics (Inst), Innocrin Pharma (Inst), Janssen (Inst), Patents, Royalties: Other
intellectual property: The ICR rewards to inventors list of abiraterone acetate; Travel,
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849P Quality of docetaxel toxicity reporting for castration resistant prostate
cancer (CRPC): A systematic review
S. Cheng, M. Qureshi, V. Arciero, K.K-W. Chan, U. Emmenegger
Medical Oncology, Sunnybrook Odette Cancer Center, Toronto, ON, Canada
Background: Prostate cancer trial design is structured following the Prostate Cancer
Clinical Trials Working Group (PCWG) guidelines which focus on harmonization of
inclusion criteria and outcome data. The PCWG, however, does not provide clear out-
lines for reporting of safety data. In fact, there is a perceived lack of widely accepted
guidelines for safety reporting.
Methods: A PubMed search of phase II and III clinical trials published until 2015
(included) was conducted using keywords “prostate cancer” and “docetaxel.”
Docetaxel-naı̈ve CRPC patients who received 75 mg/m2 docetaxel monotherapy every
three weeks were included. To assess quality of toxicity reporting, the Consolidated
Standards of Reporting Trials (CONSORT) harms checklist was adapted and each trial
scored by two independent reviewers. CONSORT scores as well as PSA and radiological
response rates over time were examined with Spearman correlation coefficients.
Univariable and multivariable linear regression examined associations between scores
and phase II versus III trials, publication year, midpoint of accrual, number of patients,
sponsor type, journal impact factor, presence of supplementary data, and geographical
region.
Results: From 21 clinical trials including 5,460 patients in docetaxel monotherapy
arms, the median CONSORT score was 15.3 (IQR 13.7–16.5) out of 22. Correlation
coefficients were not significant for all comparisons of CONSORT scores and response
rates versus years of accrual or year of publication. In univariable linear regression,
phase III clinical trials were associated with a significantly higher CONSORT score
(p¼ 0.01) as was a journal impact factor greater than 15 (p¼ 0.02). In exploratory
analyses, none of the examined factors were significant in multivariable linear
regression.
Conclusions: CONSORT scores and thus toxicity reporting quality in CRPC trials
studying docetaxel show need for improvement and should be subject to further discus-
sion. There has been no significant improvement in toxicity reporting quality over
time. It remains to be studied if our findings also apply to other agents used for the
treatment of CRPC. Legal entity responsible for the study: Sunnybrook Research
Institute.
Funding: Joseph and Silvana Melara Cancer Fund.
Disclosure: All authors have declared no conflicts of interest.
850P Intermittent short course enzalutamide in biochemically recurrent
prostate cancer: Analysis of PSA recovery, testosterone levels and
tolerability
M. Al Harthy1, H. Singh2, F. Karzai3, P. Arlen4, M. Theoret5, J. Marte3, M. Bilusic6,
A. Couvillon3, H. Owens3, A. Hankin3, L. Cordes6, I. Rosner7, J. Strauss6, W.D. Figg8,
J. Schlom9, W. Dahut6, J. Gulley6, R. Madan3
1Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA,
2Hematology and Oncology, Food and Drug Administration, Silver Spring, MD, USA,
3Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA,
4Medical Oncology, Precision Biologics, Rockville, NY, USA, 5Office of Oncology Drug
Products, Food and Drug Administration, Silver Spring, MD, USA, 6Medical Oncology,
National Cancer Institute, Bethesda, MD, USA, 7Medical Oncology, Walter Reed Medical
Center, Washington, DC, USA, 8Genitourinary Malignancies Branch, NCI /NIH, Bethesda,
MD, USA, 9Laboratory of Tumor Immunology and Biology, National Cancer Institute,
Bethesda, MD, USA
Background: Androgen deprivation therapy (ADT) and surveillance are standard
options for patients (pts) with biochemically recurrent (non-metastatic, castration sen-
sitive) prostate cancer (BCRpc) after localized therapy. Enzalutamide (enz) extends
survival in advanced prostate cancer and is being tested in earlier stages of disease.
Methods: Eligible pts had a PSA between 2.0-20.0 ng/ml, no metastatic disease, normal
testosterone (T), and a PSA doubling time of less than 12 months. Treatment for all pts
included enz 160 mg daily for 84 days (D) with/without PROSTVAC (recombinant
poxvirus PSA vaccine), but no ADT. After an amendment, pts were eligible for a 2nd
course of enz after PSA returned to baseline and confirmation of non-metastatic dis-
ease. This analysis evaluated all pts for the impact of enz on PSA and T regardless of ran-
domization as findings were similar in each group.
Results: Median age for all pts (n¼ 36) was 64 years (range: 54-85) with a median base-
line PSA of 5.02 (range: 2.02–19.43). The median PSA decline during the first course of
enz was>99% (range: 84 ->99). After enz was discontinued, the median time to first
PSA rise was 28 D (range:13–182) and median recovery to baseline PSA was 224 D
(range:84–924þ). 22 of the 36 evaluable pts received a 2ndcourse of enz. Similarly, these
patients had a median PSA decline of 99% (range 87->99). After the 2ndcourse of enz,
the median time to first PSA rise was 29 D (range:0–83) with a median time to 2nd PSA
recovery of 189 D (range:78–400). Enz was well tolerated with no grade 4 or 5 adverse
events (AEs). Grade 3 AEs included increased ALT (5%) and decreased ANC (3%). The
most common grade 2 AEs included fatigue (18%), dizziness (8%), decreased WBC
(8%), and a decreased ALC (8%). T increased above normal limits in 20/36 pts (median
Tmax¼ 834 ng/dl).
Conclusions: Intermittent, short course (84 d) enz without ADT leads to deep and pro-
longed PSA suppression below baseline in pts with BCRpc, a median of more than 7.5
months beyond treatment period. Pts who received a 2nd 84 D course of enz had similar
depth and duration of PSA suppression below baseline (more than 6.5 months after enz
treatment). Intermittent enz was well tolerated and warrants further study in BCRpc.
Clinical trial identification: NCT01875250.
Legal entity responsible for the study: National Institutes of Health/National Cancer
Institute.
Funding: National Institutes of Health.
Disclosure: P. Arlen: Stock, Salary: Precision Biologics. All other authors have declared
no conflicts of interest.
851P Pharmacokinetic/pharmacodynamic relationship of enzalutamide and
its active metabolite N-desmethyl enzalutamide in metastatic
castration-resistant prostate cancer patients
M-L. Joulia1, E. Carton Vienet Legue1, M. Allard2, O. Huillard3, M. Peyromaure4,
M. Zerbib4, M. Vidal2, F. Goldwasser1, J. Alexandre1, B. Blanchet2
1Medical Oncology, Hôpital Cochin, Paris, France, 2Clinical Pharmacology, Hôpital
Cochin, Paris, France, 3Medical Oncology, Hôpital Cochin, Paris, France, 4Urology,
Hôpital Cochin, Paris, France
Background: Enzalutamide (ENZA) is an oral androgen receptor inhibitor approved
for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC). ENZA
is extensively metabolized by CYP 3A4 into N-desmethyl enzalutamide (NDE). Based
on in vitro assays, NDE has been identified as pharmacologically active metabolite. We
aimed to explore the relationship between ENZA, NDE plasma concentration and pro-
gression-free survival (PFS) in mCRPC.
Methods: Trough plasma concentrations of ENZA and NDE were measured at steady-
state one month after treatment start, using liquid chromatography. Trough ENZA and
NDE plasma concentrations were dichotomized into 2 groups (high and low) accord-
ing to their median value. Progression was defined as clinical progression, PSA increase
or imaging progression according to the prostate working group criteria 3 or death. A
survival analysis was used to explore relationship between PFS and plasma drug
exposure.
Results: From January 2015 to May 2017, 18 mCRPC patients treated with ENZA
(median age 77.5 years, Interquartile range (IQR) 67.2-82.7) were prospectively
included. Median follow-up was 10.6 months (ms) (IQR 5.1-21.3 ms). Median trough
plasma concentration of ENZA and NDE were 10.5 6 3.7 mg/mL (Coefficient of varia-
tion (CV)¼ 33.8%; IQR 8.2-13.2) and 8.1 6 4.2 mg/mL (CV¼ 52.7%; IQR 5,4-10,1),
respectively. Pearson correlation coefficient value was 0,3 (p¼ 0.21). Eleven patients
(61%) achieved a PSA response. Median PFS in the whole cohort was 11.2 ms (IQR 3.4-
12.4). High trough plasma concentration of ENZA was associated with a shorter PFS
(9 ms vs 22.6 ms respectively in the high and the low group) (Hazard Ratio (HR) 0.2;
95% CI 0.04-0.57; p¼ 0.005). Conversely, a high trough plasma concentration of NDE
was associated with a longer PFS: 12,8 ms vs 7.2 ms respectively in the high and low
group (HR 3.04; 95% CI 1.19-48.45; p¼ 0.03).
Conclusions: Overall, these results suggest that NDE could be more pharmacologically
active than ENZA in vivo. Plasma monitoring of ENZA and NDE could lead to early
identification of patients who will not benefit from ENZA as well as to optimize their
treatment choice.
Legal entity responsible for the study: Department of Medical Oncology, Cochin
Hospital, Paris Descartes University, Pr Goldwasser.
Funding: Has not received any funding.
Disclosure: O. Huillard: Consultant/advisor: Astellas Pharma, Sanofi, Janssen
Oncology, Bristol-Myers Squibb; Travel, accommodations reimburse: Roche/
Genentech, Astellas Pharma, Pfizer; Sanofi. F. Goldwasser: Consultant/advisor:
Fresenius Kabi, Baxter. J. Alexandre: Consultant/advisor: Novartis, Roche; Honoraria:
Novartis, AstraZeneca, Roche, Ipsen; Research funding: Jansen; Travel, accommoda-
tions reimburse: Jansen. All other authors have declared no conflicts of interest.
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